Inhibikase, FDA find common ground to lift hold on Parkinson's drug

After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic.

The FDA unexpectedly placed a clinical hold on the midstage therapy IkT-148009 in November 2022, sending Inhibikase’s shares tumbling. The phase 2a trial is now set to get back on track, according to a Wednesday press release. CEO Milton Werner, Ph.D., said in the release that the company is now working quickly to re-open trial sites and get enrollment going, with the restart activities expected to be completed by the end of the first quarter.